Renal effects of long-term darbepoetin alpha treatment in hypertensive TGR(mRen2)27 rats

Abstract

Introduction: Erytropoietin (EPO) has cytoprotective and angiogenic properties and has a beneficial effect in ischaemic conditions. Since the development of renal interstitial abnormalities are often associated with ischaemia, we studied the effects of the long-acting EPO analogue darbepoetin alpha (DA) on kidney damage in TGR(mRen2)27 (Ren2) rats.

Materials and methods: Ren2 rats were randomised to DA or vehicle (VEH) or to DA + angiotensin converting enzyme inhibitor (ACEi) or VEH + ACEi. Sprague Dawley (SD) rats served as controls. Blood pressure was measured weekly and 24-h urine was collected to measure proteinuria. Blood samples were collected for creatinine and haematocrit. Kidneys were studied for inflammation and pre-fibrosis. Renal mRNA expression was studied for EPO, EPO-receptor, collagen-3α1 and kidney injury molecule-1 (KIM-1).

Results: DA had no effect on SBP, serum creatinine and proteinuria. Interstitial and glomerular α-SMA expression was significantly increased in Ren2. ACEi but not DA improved the increased renal inflammatory and pro-fibrotic profile in Ren2 rats. DA on top of ACEi further reduced glomerular α-SMA and KIM-1 expression.

Conclusion: Long-term DA treatment has no beneficial effects on renal structural and functional changes in TGR(mRen2)27 rats in the time frame studied and the dose provided.

Keywords

ACEi darbepoetin alpha hypertension kidney renin–angiotensin system Ren2

Get full access to this article

View all access options for this article.

References

Stefanski

Schmidt

Waldherr

Ritz

. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int 1996; 50: 1321–1326.

de Boer

Pokharel

Flesch

. Extracellular signal regulated kinase and SMAD signaling both mediate the angiotensin II driven progression towards overt heart failure in homozygous TGR(mRen2)27. J Mol Med 2004; 82: 678–687.

Fine

Norman

. Chronic hypoxia as a mechanism of progresion of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008; 74: 867–872.

Song

Lee

You

. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Am J Nephrol 2009; 30: 253–260.

Fliser

Haller

. Erythropoietin and treatment of non-anemic conditions – cardiovascular protection. Semin Hematol 2007; 44: 212–217.

Sharples

Yaqoob

. Erythropoietin and acute renal failure. Semin Nephrol 2006; 26: 325–331.

Sharples

Thiemermann

Yaqoob

. Mechanisms of disease: Cell death in acute renal failure and emerging evidence for a protective role of erythropoietin. Nat Clin Pract Nephol 2005; 1: 87–97.

Teng

Calvert

Sibmooh

. Acute erythropoietin cardioprotection is mediated by endotelial response. Basic Res Cardiol 2011; 106: 343–354.

Johnson

Pat

Vesey

Guan

Endre

Gobe

. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69: 1806–1813.

10.

Feng

Whitesall

Zhang

Beibel

D’Alecy

DiPetrillo

. Validation of volume–pressure recording tail-cuff blood pressure measurements. Am J Hypertension 2008; 21: 1288–1291.

11.

Kuipers

van der Harst

Kuipers

. Activation of liver X receptor-alpha reduces activation of the renal and cardiac renin–angiotensin–aldosterone system. Lab Invest 2010; 90: 630–636.

12.

Hamming

Navis

Kocks

van Goor

. Adverse renal effects of ACE inhibition during dietary sodium restriction in proteinuric and healthy rats. J Pathol 2006; 209: 129–139.

13.

de Borst

Navis

de Boer

. Specific MAP-kinase blockade protects against renal damage in homozygous TGR(mRen2)27 rats. Lab Invest 2003; 83: 1761–1770.

14.

de Borst

van Timmeren

Vaidya

. Induction of kidney injury molecule-1 in homozygous Ren2 rats is attenuated by blockade of the renin–angiotensin system or p38 MAP kinase. Am J Physiol Renal Physiol 2007; 292: F313–320.

15.

Ruifrok

Qian

Silljé

HHW

. Heart failure-associated anemia: bone marrow dysfunction and response to erythropoietin. J Mol Med 2011; 89: 377–387.

16.

Forman

Johnson

Nicol

. Erythropoietin administration protects against functional impairment and cell death after ischaemic renal injury in pigs. BJU Int 2007; 99: 162–165.

17.

Sharples

Patel

Brown

. Erythropoietin protects the kidney against the injury and disfunction caused by ischemia–reperfusion. J Am Soc Nephrol 2004; 15: 2115–2124.

18.

Yang

Hosgood

Bagul

Waller

Nicholson

. Erythropoietin regulates apoptosis, inflammation and tissue remodelling via caspase-3 and IL-1β in isolated hemoperfused kidneys. Eur J Pharmacol 2011; 660: 420–430.

19.

Spandou

Tsouchnikas

Karkavelas

. Erythropoietin attenuates renal injury in experimental acute renal failure ischaemic/reperfusion model. Nephrol Dial Transplant 2006; 21: 330–336.

20.

Vesey

Cheung

Pat

. Erythropoietin protects against ischaemic acute renal injury. Nephrol Dial Transplant 2004; 19: 348–355.

21.

Bahlmann

Song

Boehm

. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004; 110: 1006–1012.

22.

Bahlmann

Fliser

. Erythropoietin and renoprotection. Curr Opin Nephrol Hypertens 2009; 18: 15–20.

23.

Lipsic

van der Meer

Henning

. Timing of erythropoietin treatment for cardioprotection in ischemia/reperfusion. J Cardiovasc Pharmacol 2004; 44: 473–479.

24.

Westenbrink

Oeseburg

Kleijn

. Erythropoietin stimulates normal endogenitor progenitor cell-mediated endothelial turnover, but attributes to neovascularization only in the presence of local ischemia. Cardiovasc Drugs Ther 2008; 22: 265–274.